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ABSTRACT
Objective: This study aimed to determine the level of misattribution of prostate cancer deaths in
Norway based on the county of Vestfold in the years 2009–2014.
Materials and methods: The study included 328 patients registered as dead from prostate cancer
(PCD; part I of death certificate), 126 patients with prostate cancer as other significant condition at
death (OCD; part II of death certificate) and 310 patients who died with a diagnosis of prostate cancer
not registered on the death certificate (PC-DCneg) in Vestfold County in 2009–2014. The complete
cohort with patients’ names and dates of birth was provided by the Norwegian Institute of Public
Health and the Norwegian Cancer Registry. The true cause of death of all patients was evaluated based
on patient journals.
Results: Over-reporting of prostate cancer deaths in the PCD group was 33% while under-reporting in
the OCD and PC-DCneg groups was 19% and 5%, respectively. The correlation between registered and
observed causes of death was 0.81 (95% confidence interval 0.78–0.83). Misattribution of prostate can-
cer deaths increased significantly with patient age and decreasing Gleason score.
Conclusions: Prostate cancer mortality statistics in Norway are relatively accurate for patients aged
<75 years at death. However, overall accuracy of cause of death assignment is significantly reduced by
misattribution among older patients (> 75 years), who represent the large majority of prostate cancer
deaths. Over-reporting of prostate cancer deaths among elderly people may not be an exclusively
Norwegian phenomenon and may affect prostate cancer mortality statistics in other countries.
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Official cancer mortality statistics strongly influence the per-
ception of different cancers, their impact on public health
and the effects of treatment efforts [1]. The accurate deter-
mination of cancer deaths and high quality of death certifi-
cates are essential for achieving reliable mortality statistics.
However, such high-quality information is commonly only
available in clinical trials or hospital series.
Norway and other Scandinavian countries report consist-
ently higher prostate cancer mortality rates than other
Western countries [1,2]. Several explanations for this have
been suggested, among them a potentially higher underlying
risk of prostate cancer death and differences in national
health strategies regarding screening and treatment [2]. In
1981, Percy et al. documented that misattribution of cause of
death in death certificates may bias mortality statistics [3].
Several studies have since corroborated this evidence [4–6].
For prostate cancer, there is compelling evidence that
increasing prevalence due to screening has significantly
affected misattribution of prostate cancer deaths [7].
Several Scandinavian studies have addressed the quality
of death certificates with regard to prostate cancer, demon-
strating relatively reliable results with misattribution rates of
10% or less [8–11]. However, previous audits of prostate can-
cer deaths have been either registry based [10,11] or con-
ducted in study patients who were considerably younger at
death than the majority of men dying of prostate cancer
[8,9]. Correct attribution of the underlying cause of death
becomes more challenging with increasing age owing to
competing comorbidities [12]. A recent Norwegian study,
comparing relative and cause-specific survival for several can-
cer sites, documented significant differences for older pros-
tate cancer patients, suggesting incorrect coding of the
underlying cause of death [13].
Increasing prostate cancer incidence rates in Norway and
the likely corresponding increase in prevalence of non-lethal
cancers may potentially exacerbate this problem of misattri-
bution bias.
The aim of this population-based study was to determine
the level of misattribution of Norwegian prostate cancer
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Vestfold Hospital Trust is the only hospital in Vestfold
County, which has approximately 230,000 inhabitants repre-
senting approximately 5% of the Norwegian population.
Vestfold County has a somewhat higher proportion of men
older than 70 years than the rest of Norway, but is otherwise
representative of the entire country in terms of relevant soci-
oeconomic factors (see supplementary material).
For the 6 year period 2009–2014, names and dates of
birth of all deceased men in Vestfold County, registered with
either prostate cancer as the immediate/underlying cause of
death (part I of the death certificate, n¼ 341) or another sig-
nificant condition at death (part II of the death certificate,
n¼ 127), were obtained from the Norwegian Institute of
Public Health, while data on all deceased men with prostate
cancer whose diagnosis was not mentioned on the death
certificate were obtained from the Norwegian Cancer
Registry.
Prostate cancer care for almost all patients in the county
of Vestfold is provided at Vestfold Hospital Trust, including
diagnosis, treatment and follow-up. Patients from two periph-
eral municipalities, who routinely receive their prostate can-
cer care elsewhere, were excluded from the study. This
resulted in a study population of 328 patients with prostate
cancer as an immediate or underlying cause of death (part I
of the death certificate), referred to as PCD; 126 patients with
prostate cancer as other significant condition (part II of the
death certificate), referred to as OCD; and 310 patients with
prostate cancer without any mention of prostate cancer on
the death certificate, referred to as PC-DCneg (Norwegian
Cancer Registry).
Assessment of cause of death
A review committee was formed consisting of three urolo-
gists and one oncologist, all of whom were experienced in
treating prostate cancer patients. Three consecutive reviews
of the study population were conducted. Patient hospital
records provided sufficient information on medical histories
for the great majority of patients. For 12 patients, additional
information had to be obtained from nursing homes or fam-
ily doctors.
First review of patient history
The first review served as a filtering process and identified
patients with an unambiguous, immediate cause of death
and a clear underlying disease process, separating out
patients ascribed as either dead from prostate cancer (PCD)
or dead from other causes (OCD). The review was conducted
by the first author, with a blinded audit of 50 random
patients in the sample by two other committee members
demonstrating perfect correlation.
Prostate cancer death was assumed when the immediate
cause of death was caused by systemic or local complications
of the disease process or cancer-directed treatment and
comorbidities were either absent or only of minor import-
ance. Death from other causes was defined by the criteria
listed in Table 1.
Patients who could not be placed with certainty in either
of the above categories were included in the second review
for further evaluation.
Patients who had been autopsied were registered with
the underlying cause of death given on the autopsy report,
and no further review of the cause of death was conducted
(n¼ 16).
Second review of patient history
Patients were independently reviewed by committee mem-
bers unaware of the other reviews. Prostate cancer death
was assumed when the immediate cause of death was due
to systemic or local complications of the disease process or
cancer-directed treatment. The following categories were
assigned, answering the question of whether the patient’s
death was due to prostate cancer: ‘Yes/No’ (preferable cat-
egory), ‘Likely/Unlikely’ (if a definite answer was not possible)
or ‘Not possible to determine’ (if any qualified answer was
impossible to give, owing to numerous and competing
comorbidities). Patients on whom committee members
reached conflicting conclusions were included in the third
review.
Third review of patient history
Patients whose underlying cause of death was still undeter-
mined after the first two reviews were discussed in a consen-
sus meeting with all members of the committee present.
Patient histories were reviewed in plenum and a consensus
decision was reached upon which all committee members
could agree. Assignment of labels followed the same rules as
outlined under the second review of patient history.
Final result
All patients with the label ‘Yes’ or ‘Likely’ after the third
review were collapsed into the final Yes category (dead from
prostate cancer). Patients labeled ‘No’ or ‘Unlikely’ were
Table 1. First review of patient history: definition of death from other causes
for patients with prostate cancer as underlying of immediate cause of
death (PCD, n = 328) and corresponding results.
No. of patients (%)
No histological or clinical diagnosis of prostate
cancer
15 (4.6)
Watchful waiting with no significant disease activity 13 (4)
Previous radical treatment with no disease recur-
rence and an immediate cause of death not
related to treatment
5 (1.5)
Hormone therapy with complete response to treat-
ment and an immediate cause of death unrelated
to hormone therapy, and other
33 (10.1)
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collapsed into the final No category (not dead from prostate
cancer). ‘Not possible to determine’ was upheld as an inde-
pendent category.
Statistics
Baseline data and prostate cancer death misclassification
rates were described by median, range and percentages.
Confidence intervals (CIs) for percentages were calculated
using Wilson score interval with Yates’ continuity correction.
The effect of age and study year on the risk of misclassifying
cause of death was studied by binary logistic regression.
Subgroup analysis was performed by dividing patients into
seven age groups (< 65, 65–70, 70–75, 75–80, 80–85, 85–90,
and >90 years). All statistical analyses were conducted using
SPSS statistics, version 23 (IBM Corp., Armonk, NY, USA) and
the R statistical package [14]. Correlation between the cause-
of-death methods was calculated using Cohen’s kappa.
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics (REK).
Results
The median age at death was 83–84 years in all groups. In
the PCD group, 21% of patients were younger than 75 years
at death, with corresponding numbers of 14% in the OCD
group and 16% in the PC-DCneg group (n¼ 70, n¼ 18,
n¼ 50), while 14% of patients in the PCD group, 20% in the
OCD group and 14% in the PC-DCneg group were older than
90 years at death (n¼ 46, n¼ 25, n¼ 43). Dementia had been
diagnosed in 18% of the PCD patients, 11% of the OCD
patients and 10% of the PC-DCneg patients (n¼ 58, n¼ 14,
n¼ 32). Fifteen patients in both the PCD and OCD groups
and two patients in the PC-DCneg group had no clinical or
histological diagnosis of prostate cancer. The clinical charac-
teristics of all patients are listed in Table 2.
Death from prostate cancer (PCD)
The first review of the PCD group identified 21% of patients
(n¼ 70) who had died of causes other than prostate cancer.
Their prostate cancer status at death is listed in Table 1. The
final result of the review process demonstrated that 32% of
Table 2. Comparison of clinical characteristics of patients with prostate cancer as the immediate or underlying cause of
death according to the death certificate (PCD), patients with prostate cancer as other significant condition at death (OCD)
and patients with prostate cancer with no mention of the diagnosis on the death certificate (PC-DCneg).
PCD patients OCD patients PC-DCneg patients
All patients
No. of patients 328 126 310
Age at death (years) 84 (50–97) 84 (59–98) 83 (57–101)
Patients with prostate cancer
No. of patients 313 111 308
Year of diagnosis 1989–2014 (2007) 1988–2014 (2005) 1985–2013 (2005)
Age at diagnosis (years) 76 (48–96) 76 (52–93) 75 (55–96)
Age at death (years) 83 (50–97) 83 (59–98) 83 (57–101)
PSA at diagnosis (mg/l) 34 (0–10 000) 21 (1–2853) 15 (0–4400)
Gleason score at diagnosis
 6 29 (9) 23 (21) 106 (35)
7 102 (33) 36 (32) 119 (39)
8–10 128 (41) 34 (31) 54 (18)
Unknown 54 (17) 18 (16) 29 (9)
T stage
T1 44 (14) 21 (19) 117 (38)
T2 41 (13) 14 (13) 65 (21)
T3 140 (45) 59 (53) 100 (33)
T4 48 (15) 9 (8) 17 (6)
Unknown 40 (13) 8 (7) 9 (3)
Metastatic status at diagnosis
Yes 106 (34) 18 (16) 30 (10)
No 178 (57) 85 (77) 268 (87)
Unknown 29 (9) 8 (7) 10 (3)
Metastatic status at death
Yes 230 (74) 26 (23) 22 (7)
No 63 (20) 84 (76) 279 (91)
Unknown 21 (6) 1 (1) 7 (2)
Primary treatment
Hormone therapy 223 (71) 55 (50) 110 (36)
Radical prostatectomy 11 (4) 9 (8) 26 (8)
Radiation therapy 15 (5) 9 (8) 31 (10)
Watchful waiting 61 (20) 37 (33) 115 (37)
Active surveillance 5 (2)
Autopsy finding 2 (1)
Cystoprostatectomy (bladder cancer) 15 (5)
Other 3 (1) 1 (1) 4 (1)
Time from diagnosis to death (years) 5 (0–22) 6 (0–22) 6 (0–27)
Hormone therapy at death 284 (91) 82 (74) 143 (46)
mCRPC at death 200 (64) 39 (35) 40 (13)
Data are shown as n, median (range) or n (%).
PSA: prostate-specific antigen; mCRPC: metastatic castration-resistant prostate cancer.
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patients (n¼ 105) in the PCD group had died of other causes.
Logistic regression demonstrated a statistically significant
increase in misattribution rates with increasing age in the
PCD group (p< 0.001, OR 1.8 per 5 years, 95% CI 1.4–2.1).
Among patients younger than 75 years, 10% (7/70) were
incorrectly labeled as dead from prostate cancer while the
misattribution rate increased to 63% in patients aged 90
years and older (29/46). Misattribution of cause of death per
age group in the PCD group is illustrated in Figure 1. Logistic
regression revealed a statistically significant impact on mis-
attribution rates by Gleason grade (p¼ 0.007, OR 0.7, 95% CI
0.5–0.9). There was no statistically significant variation in mis-
attribution rates for the years of diagnosis 2009–2014
(p¼ 0.25, OR 1.1, 95% CI 1.0–1.2) or for tumor stage at diag-
nosis (p¼ 0.12, OR 0.8, 95% CI 0.6–1.1).
Death from other causes (OCD)
In the OCD group, the final results of the review process indi-
cated that 18% of patients (n¼ 23) had died of prostate can-
cer. Logistic regression showed a statistically non-significant
decreasing trend of misattribution by age in the OCD group
(p¼ 0.33, OR 1.2 per 5 years, 95% CI 0.9–1.6). Misattribution
of cause of death per age group in the OCD group is illus-
trated in Figure 2. Gleason grade had a statistically significant
impact on misattribution (p¼ 0.006, OR 0.5, 95% CI 0.3–0.8).
There was no statistically significant variation in misattribu-
tion rates for year of diagnosis (p¼ 0.18, OR 0.8, 95% CI
0.6–1.1) or stage at diagnosis (p¼ 0.25, OR 0.7, 95% CI
0.4–1.3).
The review process of PCD and OCD patients and its
results are illustrated in Tables 3 and 4.
Patients with prostate cancer not registered on the
death certificate (PC-DCneg)
Among the 310 PC-DCneg patients, the review process identi-
fied 5% (n¼ 14) who had died of prostate cancer.
Underreporting of prostate cancer deaths in the OCD
and PC-DCneg groups was 18% and 5%, respectively, while
over-reporting in the PCD group was 32% (Figure 3).
The correlation between reported patient death and
observed patient death was 0.81 (95% CI 0.78–0.83), with
Cohen’s kappa (0.4, 95% CI 0.3–0.5) showing a moderate
correlation between registered and true prostate cancer
death.
Discussion
In a cohort of 328 consecutive patients with prostate cancer
as cause of death, this study found that one-third died of
other causes, while among 436 patients with prostate cancer
who died of other causes approximately one-tenth died of
prostate cancer. The net result was a considerable over-regis-
tration of prostate cancer deaths in Vestfold County for the
years 2009–2014.
This study has several strengths: its population-based
design, the consecutive cohort of patients, the 6 year study
period and rich clinical data for the majority of patients. The
weaknesses of the study are its limited geographical scope
and the difficult clinical decision-making process, which
might be biased. The committee members in this study treat
prostate cancer patients daily. A panel of physicians from
other specialties may have come to different conclusions for
some of the study patients.
Figure 1. Total number of patients registered as dead from prostate cancer per age group: patients dead from prostate cancer (blue), patients dead from other
causes (green) and patients whose cause of death was not possible to determine (yellow).
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The findings seem to contradict previous studies which
documented relatively reliable mortality numbers for prostate
cancer in Norway [10,11]. However, these studies were regis-
ter based and evaluated prostate cancer deaths that occurred
in 1996, before the PSA-induced increase in prostate cancer
prevalence. Feuer et al. demonstrated during the early PSA
era that rising prostate cancer prevalence rates were mir-
rored directly by corresponding changes in mortality rates
[7]. The authors hypothesized that a fixed percentage of the
rising and falling pool of newly diagnosed prostate cancer
patients was mislabeled as dying of the disease [7].
According to this theory, it is likely that misattribution rates
in Norway have increased considerably during the past dec-
ade (2004–2013) as prostate cancer prevalence has doubled
at least partly owing to extensive PSA testing [15]. Prostate
cancer prevalence is equal in Vestfold County and on the
national level, suggesting that misattribution rates may be
comparable [16]. A more recent study by the Norwegian
Cancer Registry demonstrated that relative survival estimates
for prostate cancer were consistently above cause-specific
survival estimates for all but the very youngest patients, with
the most marked differences among the oldest patients (>85
years) [13]. One explanation suggested by the authors is that
prostate cancer patients in Norway are somewhat healthier
Figure 2. Total number of patients registered as dead from other causes per age group: patients dead from prostate cancer (blue), patients dead from other causes
(green) and patients whose cause of death was not possible to determine (yellow).
Table 3. Results of the review process for patients with prostate cancer as the immediate or underlying cause of death (PCD) (n¼ 328).
Prostate cancer death
First review Second review Third review Final result
% (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n
Yes 58 (52–63) 189 60 (54–65) 195 62 (56–67) 202 67 (61–72) 218
No 21 (17–26) 70 26 (21–31) 85 29 (24–34) 94 32 (27–37) 105
Likely – – 2 (1–4.5) 7 5 (3–8) 16 – –
Unlikely – – 0.3 (0–2) 1 3 (2–6) 11 – –
Not possible to determine – – 0.6 (0–2) 2 2 (1–4) 5 2 (1–3) 5
Further discussion needed 21 (16–26) 69 12 (8–16) 38 – – – –
CI: confidence interval.
Table 4. Results of the review process for patients with prostate cancer as other significant condition at death (OCD) (n¼ 126).
Prostate cancer death
First review Second review Third review Final result
% (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n
Yes 14 (8–21) 17 15 (10–23) 19 16 (10–24) 20 18 (12–26) 23
No 66 (57–74) 83 72 (63–79) 90 75 (66–82) 94 79 (70–85) 99
Likely – – 0.8 (0–5) 1 2 (1–7) 3 – –
Unlikely – – 2 (0–6) 2 4 (2–10) 5 – –
Not possible to determine – – 0.8 (0–5) 1 3 (1–8) 4 3 (1–8) 4
Further discussion needed 21 (14–29) 26 10 (6–17) 13 – – – –
CI: confidence interval.
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than the general population. However, as the observed effect
is strongest among the oldest patients, the reported differen-
ces are more likely to be due to incorrect coding of the
underlying cause of death. This is mirrored by the patients in
the present study whose cause of death could not be deter-
mined during the first review: the median age in this sub-
group was 86 years and for the majority a cause of death
could first be determined after the third review. For patients
younger than 75 years, on the other hand, results were rela-
tively reliable, with a 90% concordance between cause of
death on the death certificate and cause of death based on
committee evaluation. However, these patients were a clear
minority in the PCD group (21%), where 75% of patients
were older than 77 years at death.
A further explanation for the high misattribution rates in
this study may be found in the Norwegian proceedings for
death certification [17,18]. In contrast to many other Western
countries, death certificates in Norway are filled out by the
doctor who confirms the patient’s death. These are usually
the most junior doctors at the hospitals or on-call doctors at
the municipal primary care emergency departments and
nursing homes, who rarely have intimate knowledge of the
patient’s medical history. In 1986, 57% of Norwegian prostate
cancer deaths occurred in hospitals, where determination of
the cause of death is usually more accurate [19], while only
29% occurred in nursing homes. By 2014 these numbers
were reversed, with more than 60% of prostate cancer deaths
occurring in nursing homes and only 23% in hospitals (2016
mail correspondence between the Norwegian Institute of
Public Health and the first author). This change may have
impacted the accuracy of death certificates considerably.
Furthermore, it seems that not all doctors are fully confident
with the concepts of immediate, underlying and contributory
causes of death. In addition, the guidelines from the WHO
state that in certain circumstances a specific diagnosis in part
II of the death certificate may be registered as the underlying
cause of death instead of an unspecific diagnosis in part I.
This will have little impact on the actual cause of death in
patients with a cancer diagnosis and few or no comorbidities.
However, in patients with several comorbidities, usually older
patients, this lack of knowledge may have a considerable
impact on accuracy.
A key issue is the interpretation of the results and the
question of whether over-registration of prostate cancer
deaths is a specific Norwegian problem. In this case, prostate
cancer mortality may not be significantly higher in Norway
than in other Western countries. A Swedish registry-based
study, evaluating the quality of official cause of death diag-
noses of prostate cancer patients diagnosed in 1987–1999
and deceased before 2003, documented a relatively high reli-
ability (correlation of 0.86%) of official cause of death statis-
tics [20]. However, the hallmarks of misattribution of cause of
death are similar to those in the present study, with high
correlation among the youngest patients and increasing mis-
attribution with increasing age. The higher misattribution
rates seen in the current study may be due to the more
recent timeframe of this study, with higher underlying preva-
lence rates of prostate cancer.
Further results of death certificate audits have been pub-
lished for Finnish, Swedish and UK prostate cancer patients
[8,9,21,22], demonstrating high accuracy of death certificates
in those countries, while a similar evaluation in a group of
US prostate cancer patients showed more ambivalent results
[23]. However, patients evaluated in these studies were par-
ticipants in clinical trials and were on average significantly
younger at death than prostate cancer patients in the
Figure 3. Patient transition from the original group of patients registered as dead from prostate cancer (PCD) and formation of the group of patients observed
dead from prostate cancer. OCD: dead from other causes; PC-DCneg: prostate cancer not registered on the death certificate.
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general population (maximum age at death 74–77 years in
the Finnish and Swedish clinical trials). The majority of pros-
tate cancer deaths occur in patients older than 80 years and
thus similar quality issues as described in the present study
may negatively affect the prostate cancer mortality statistics
in the above-mentioned countries. In this case, prostate can-
cer mortality may still be relatively high in Norway, with
excess mortality among patients older than 80 years. This
may be due to national therapy recommendations where,
until recently, a strict age limit (75 years) for recommending
radical therapy has been observed.
Prostate cancer mortality statistics in Norway must be
interpreted with caution and may have to be supplemented
by additional parameters (e.g. statistics on patients with cas-
tration-resistant prostate cancer) that may better reflect dis-
ease burden and intervention effects in the general
population.
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